Lake Street Capital Lowers OptimizeRx (NASDAQ:OPRX) Price Target to $20.00

OptimizeRx (NASDAQ:OPRX) had its price target reduced by stock analysts at Lake Street Capital from $24.00 to $20.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital’s price objective indicates a potential upside of 196.74% from the stock’s current price.

Several other analysts have also recently issued reports on the stock. Citizens Jmp boosted their price objective on shares of OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. B. Riley Financial reaffirmed a “buy” rating and issued a $11.00 target price (down from $28.00) on shares of OptimizeRx in a research report on Friday. Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. Stephens lowered their price target on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Roth Mkm dropped their price target on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Friday. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.57.

OptimizeRx Price Performance

OPRX opened at $6.74 on Friday. OptimizeRx has a 1 year low of $3.99 and a 1 year high of $22.25. The company’s 50 day simple moving average is $10.52 and its 200 day simple moving average is $14.72. The stock has a market capitalization of $125.63 million, a PE ratio of 25.92 and a beta of 1.20. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.81%. As a group, sell-side analysts expect that OptimizeRx will post -0.33 EPS for the current year.

OptimizeRx declared that its Board of Directors has approved a share buyback program on Thursday, March 5th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds have recently modified their holdings of OPRX. CenterBook Partners LP acquired a new position in OptimizeRx during the 3rd quarter worth approximately $6,331,000. Next Century Growth Investors LLC grew its position in OptimizeRx by 139.8% in the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after acquiring an additional 294,688 shares in the last quarter. Manatuck Hill Partners LLC grew its position in OptimizeRx by 139.5% in the second quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock valued at $6,142,000 after acquiring an additional 265,000 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of OptimizeRx by 42.8% during the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after purchasing an additional 202,446 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of OptimizeRx during the third quarter valued at approximately $4,081,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx News Roundup

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.